Bulimia Nervosa
📧 Sign up to get email alerts when something new happens for Bulimia Nervosa.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2014-10-07Clinical Trial Update: Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa
Completed clinical trial examining self-regulatory control and eating behavior in bulimia nervosa using neuroimaging.
-
FDA approval · 2014-09-11FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approves a supplemental application for Fluoxetine hydrochloride (fluoxetine) from PAI Holdings, LLC dba PAI Pharma.
-
CLINICAL_TRIALS research · 2014-08-21Clinical Trial Update: Examining Common Substrates of Eating and Alcohol Use Disorders
The clinical trial examining shared substrates of eating disorders and alcohol use disorders has completed.
-
CLINICAL_TRIALS trial_result · 2014-08-15Clinical Trial Update: Imaging the Dopamine Systems in Bulimia Nervosa
This clinical trial studied imaging of dopamine systems in individuals with bulimia nervosa. The study status is completed.
-
FDA approval · 2014-08-11FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for a fluoxetine hydrochloride generic product submitted by PAI Holdings (PAI Pharma).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-07-18FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.
-
FDA approval · 2014-07-18FDA Approved: FLUOXETINE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for a fluoxetine hydrochloride generic from Lannett Company, Inc.
-
FDA approval · 2014-07-17FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for Fluoxetine from Aurobindo Pharma Limited, indicating continued approval of this generic produc…
-
FDA approval · 2014-07-16FDA Approved: FLUOXETINE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for a generic fluoxetine hydrochloride product from Lannett Company, Inc. The approval authorize…
-
FDA approval · 2014-07-11FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for fluoxetine from Aurobindo Pharma Limited, authorizing a new generic fluoxetine product under…
-
CLINICAL_TRIALS trial_result · 2014-03-05Clinical Trial Update: N-acetylcysteine in the Treatment of Bulimia Nervosa [Phase 3]
Phase 3 trial evaluating N-acetylcysteine for bulimia nervosa was terminated.
-
CLINICAL_TRIALS research · 2014-02-26Clinical Trial Update: Improving Patient Outcome in Group Therapy for Eating Disorders [Phase 2, Phase 3]
This clinical trial update outlines Phase 2 and Phase 3 studies of group therapy for eating disorders. The conditions include bulimia nervos…
-
CLINICAL_TRIALS research · 2013-11-21Clinical Trial Update: Neurobiology of Eating Disorders Treatments [NA]
This entry reports the completion of a University of Turin-led study investigating neurobiological approaches to treating anorexia nervosa a…
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: Family Therapy for Adolescent Bulimia Nervosa [Phase 2]
Phase 2 clinical trial of family therapy for adolescents with Bulimia Nervosa has completed.
-
CLINICAL_TRIALS trial_result · 2013-08-12Clinical Trial Update: Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder [NA]
A completed clinical trial evaluates the effectiveness of baclofen in treating bulimia nervosa and binge eating disorder.
-
CLINICAL_TRIALS trial_result · 2013-07-30Clinical Trial Update: Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa [Phase 2]
Phase 2 trial evaluating antibiotic treatment for bulimia nervosa with outcomes on binge eating and digestive function; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2013-05-10Clinical Trial Update: N-acetylcysteine in Bulimia Nervosa [Phase 2, Phase 3]
A Phase 2/3 clinical trial of N-acetylcysteine for bulimia nervosa was terminated.
-
CLINICAL_TRIALS research · 2013-03-08Clinical Trial Update: Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
This completed clinical trial investigated the association between attention-deficit/hyperactivity disorder and bulimia nervosa in outpatien…
-
FDA approval · 2013-01-03FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
The FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.
-
CLINICAL_TRIALS trial_result · 2012-10-26Clinical Trial Update: Cognitive Behavioral Therapy for Adolescents With Bulimia [NA]
This update indicates that a clinical trial evaluating cognitive behavioral therapy for adolescents with bulimia nervosa has completed.
-
CLINICAL_TRIALS trial_result · 2012-10-26Clinical Trial Update: Cognitive Behavior Therapy for Adolescents With Bulimia [NA]
A clinical trial evaluating cognitive behavioral therapy for adolescents with bulimia nervosa has completed.
-
FDA approval · 2012-10-01FDA Approved: FLUOXETINE — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved the original (ANDA) application for fluoxetine from Heritage Pharmaceuticals (d/b/a Avet), confirming a generic formulation of …
-
FDA approval · 2012-09-27FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fluoxetine from Aurobindo Pharma Limited, allowing the generic product to be marketed under the …
-
FDA approval · 2012-07-31FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for fluoxetine hydrochloride from PAI Holdings (PAI Pharma), confirming approval of a generic fluoxe…
-
CLINICAL_TRIALS trial_result · 2012-06-12Clinical Trial Update: An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder [NA]
Open-label trial investigating memantine for bulimia nervosa and body dysmorphic disorder. The study is completed and results were posted on…